What the FDA labels say about taking them together
Enalapril and sacubitril/valsartan
Enalapril's FDA label of January 23, 2026 names sacubitril/valsartan in its contraindications section; sacubitril/valsartan's label does not name enalapril itself but warns about its class (ACE inhibitors). The enalapril label: “Do not administer EPANED within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor.”
Check it at the source: the enalapril FDA label on DailyMed (effective January 23, 2026, Bausch Health US LLC); the sacubitril/valsartan FDA label on DailyMed (effective July 6, 2026, Novartis Pharmaceuticals Corporation).
What does the enalapril label say about sacubitril/valsartan?
Enalapril label, contraindicationsDo not administer VASOTEC within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS , Head and Neck Angioedema ).
Source: FDA drug label (Epaned, NDA208686), Azurity Pharmaceuticals, Inc., effective December 16, 2025 (SPL set e6dbda02-779e-420c-893d-d0fea09432be), via openFDA
Source: FDA drug label (Vasotec), Bausch Health US LLC, effective January 23, 2026 (SPL set 39631f1f-5d19-43c1-b504-bf56d991ed97), via openFDA; the full label on DailyMed
What does the sacubitril/valsartan label say about enalapril?
Sacubitril/valsartan's label does not name enalapril itself; it warns about its class (ACE inhibitors):
Sacubitril/valsartan label, contraindicationsCONTRAINDICATIONS ENTRESTO is contraindicated: in patients with hypersensitivity to any component in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy [see Warnings and Precautions (5.2)] with concomitant use of ACE inhibitors.
Sacubitril/valsartan label, drug interactionsBlockade of the Renin-Angiotensin-Aldosterone System Concomitant use of ENTRESTO with an ACE inhibitor is contraindicated because of the increased risk of angioedema [see Contraindications (4)].
Source: FDA drug label (ENTRESTO), Novartis Pharmaceuticals Corporation, effective July 6, 2026 (SPL set 000dc81d-ab91-450c-8eae-8eb74e72296f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Enalapril | Sacubitril/valsartan | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | Heart failure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0664 per tablet 10 mg tablet | $0.533 per unit 49-51 mg |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once